A recent clinical trial studied urate-lowering with benzbromarone
in patients with CHF [50]. While there was no
effect on the altered haemodynamics in these CHF patients,
lowering urate did improve insulin resistance. However,
it cannot be excluded that it may have been a
secondary pharmacological effect of benzbromarone related
to its PPAR agonist activity. In a small Polish study,
28 patients with CKD were switched from a regular fructose
diet to a low fructose diet for 6 weeks, and then back
again. There were significant reductions in fasting serum
insulin and inflammatory biomarkers, and a trend toward
reductions in serum urate and blood pressure [66].